Clinical Trial Update: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sorafenib with transarterial chemoembolization in hepatocellular carcinoma with portal vein invasion was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED